BioSpace News Archive

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced study results of 926 women demonstrating that DCISionRT, the 7-gene biosignature for patients with ductal carcinoma in situ, reclassified Clinical Pathologic Low-Risk patients defined by RTOG-9804 and MSKCC-like DCIS models as DCISionRT High-Risk.

Guangzhou Magpie Pharmaceuticals announced its submission of a poster presentation at the XXVI World Congress of Neurology (WCN 2023), showcasing Phase II data of their leading asset, TBN, and its significant success in improving key markers of ALS disease progression.

OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data presentations at the 22nd Annual NEALS (Northeast ALS Consortium) meeting being held October 4 - 6, 2023 in Clearwater Florida.

Molecular testing laboratories using College of American Pathologists (CAP) proficiency testing (PT) programs exhibit excellent testing performance based on a recent reanalysis of a pilot study that was published in the Archives of Pathology & Laboratory Medicine.

Aviv Clinics, one of the world’s most advanced brain clinics, shares the results of a new case report showing a unique hyperbaric oxygen therapy (HBOT) protocol was effective for improving hand motor function in a chronic post-stroke patient.

A multidisciplinary group of researchers from Children’s Hospital of Philadelphia and Penn Medicine have received a $50 million grant from the National Institutes of Health to study the impact of environmental influences on pregnancy and children’s health.

Geistlich Pharma North America Inc. is pleased to announce that our Executive Chairman, Dr. Andreas Geistlich, has been awarded the prestigious American Association of Oral and Maxillofacial Surgeons Board of Trustees Special Citation Award for the company’s exceptional and longstanding contributions to the field of Oral and Maxillofacial Surgery.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its clinical portfolio at the company’s R&D Day.

Piccolo Medical, Inc. (Piccolo) today announced the close of a $5.5M Series B financing led by Event Capital Strategies, a medical technology-focused investment fund based in New York.

The National Committee for Quality Assurance and the American Diabetes Association® announced the release of a new white paper titled, Digital Technology-Enabled Care Models for Diabetes: A Framework for Developing Quality Standards and Measures.